Does Wellcare Cover Wegovy? The 2026 Answer Depends on Two Things

Disclosure: The RX Index may earn a commission if you use certain provider links on this page. Compensation does not change Medicare or Wellcare coverage rules, the evidence below, or which treatment path we tell you to take.

Does Wellcare cover Wegovy? Sometimes. Wellcare Part D cannot cover Wegovy when it is prescribed only for weight management, but eligible Wellcare members with qualifying Medicare Part D coverage may get it for a $50 copay per covered monthly fill through Medicare's separate GLP-1 Bridge. Wellcare Part D may cover Wegovy for cardiovascular-risk reduction or MASH when the exact plan and clinical criteria are met.

For the broader Wellcare drug-list comparison — including Value Script versus Classic tiers, Soliqua, and the current GLP-1 coverage map — see Best GLP-1 on Wellcare Formulary: What's Covered in 2026.

That last part is where nearly everyone gets stuck. Including, as it turns out, Wellcare's own member website.

We pulled two documents Wellcare published — one written for members, one written for doctors — and they tell you different things. The member page says the new program still has no final access details. The provider bulletin, dated July 9, 2026, says the program is live, explains exactly how to get into it, and states plainly that Wellcare itself can't touch it.

The provider bulletin has the current operational information. You probably haven't seen it. This page is that bulletin, translated — then checked against CMS, Medicare, the FDA, current Wellcare formularies, and the actual cash-pay terms.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Does Wellcare cover Wegovy for weight loss, heart risk, or MASH?

The answer depends first on why Wegovy is prescribed, and second on what kind of Wellcare coverage you have. Weight-management-only use belongs in Medicare's separate GLP-1 Bridge when every eligibility rule is met; cardiovascular-risk reduction and Wegovy injection for MASH belong in Wellcare's normal Part D process; Medicaid-only coverage is state-specific.

What we actually verified before publishing this answer

• The Bridge is live from July 1, 2026 through December 31, 2027.
• Eligible members have a $50 copay, and the payment does not count toward the Part D deductible or TrOOP.
• Wellcare cannot accept or process Bridge prior authorizations, claims, or reimbursements.
• CMS's plan-type, clinical, diagnosis, prescribed-use, and 2026 Part D claim-history rules.
• The current FDA-approved Wegovy uses and formulation differences.
• Wegovy's absence from three sampled official Wellcare formularies marked updated August 1, 2026.
• Current Novo Nordisk self-pay terms and Ro's membership and government-insurance policy.

We did not submit a member claim or prior authorization, access a member account, or verify every Wellcare plan.

This page is for you if you have Wellcare Medicare drug coverage — a standalone drug plan, a Medicare Advantage plan with drug coverage, a Special Needs Plan, or an eligible employer/union Part D plan — and you want to know whether Wegovy has a real covered treatment path.

This page can still help if your card says WellCare but your coverage is Medicaid rather than Medicare. Skip to the Medicaid section before applying any Medicare rule to your case.

This page is not a guarantee of approval, a clinical eligibility decision, or a list of telehealth companies that magically “accept Wellcare” for the medication. A doctor can accept Wellcare for a visit and still be unable to get the drug paid for. The diagnosis, plan type, processor, formulary, documentation, and pharmacy claim all have to line up.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

→ Check which Wegovy treatment path fits your Wellcare coverage — personalized in about two minutes.

Why Wellcare Part D can't cover Wegovy for weight management alone

Basic Medicare Part D excludes drugs when they are used only for weight loss. That's a federal benefit rule, not a judgment by your pharmacist and not a Wellcare-specific decision. The separate Medicare GLP-1 Bridge is the new treatment path for eligible Part D members seeking covered GLP-1 treatment solely for weight management.

Here's the part almost nobody explains, and it's worth 30 seconds because it changes how the rest of this reads.

When your pharmacist says ordinary Medicare Part D doesn't cover Wegovy for weight management, they're not making a judgment about you. They're applying the statutory exclusion that governs the basic Part D benefit.

But the same drug can be a Part D drug when it is prescribed for another FDA-approved use that Part D is allowed to cover. CMS applied that distinction after Wegovy received its cardiovascular indication: weight-management-only use remains excluded from basic Part D, while the covered non-weight-loss indication can go through Part D.

That single distinction is why this page has three sections instead of one.

Wegovy injection has three FDA-approved uses

MASH stands for metabolic dysfunction-associated steatohepatitis — a serious fatty liver disease that used to be called NASH. The MASH indication applies to the Wegovy injection, not the tablet, and the FDA granted accelerated approval based on improvement in MASH and fibrosis while confirmatory evidence continues.

The Wegovy tablet is FDA-approved for chronic weight management in eligible adults and for reducing major cardiovascular-event risk in the labeled adult population. It is not labeled for MASH.

Same brand. Different approved uses — and MASH applies to injection only. The medically supported reason for the prescription determines which coverage system has to evaluate it.

Primary sources: Wellcare's Medicare weight-loss drug page · FDA cardiovascular approval · FDA MASH approval · Current Wegovy prescribing information

What changed on July 1, 2026 — and what Wellcare's member page still says

On July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a temporary federal program that gives eligible Medicare Part D members access to specified GLP-1 drugs for weight management at a fixed $50 copay per covered monthly fill through December 31, 2027. The Bridge operates outside the Part D benefit, so Wellcare neither approves nor pays a Bridge claim.

We compared two documents Wellcare published about this program. Here's what we found.

Wellcare's member-facing page, the one a member would find by searching, still says CMS has not provided final details on qualification, enrollment, or access and points to possible Medicare participation as early as 2027.

Wellcare's provider bulletin, dated July 9, 2026, says the program launched July 1, lists the included medications, summarizes the clinical thresholds, gives the copay, walks a prescriber through the process, and provides the provider support number.

Both are live on wellcare.com right now. A member reading the first page could reasonably conclude there's nothing to do yet. A doctor reading the second has the current operational instructions.

We want to be fair about this, because fairness is the point. Wellcare isn't hiding anything, and Wellcare is correct about the ordinary Part D exclusion. A consumer education page lagging a fast-moving federal demonstration is ordinary. But right now, in August 2026, the gap between those two pages can send people down the wrong treatment path and waste time.

If your Wellcare representative hasn't mentioned the Bridge, that is not evidence it doesn't apply to you. It also isn't evidence that you qualify. The correct answer comes from your plan type, the prescribed use, CMS's clinical criteria, and the central processor's eligibility check.

One more thing we noticed while reading the current CMS materials: the Medicare portion of the BALANCE Model is not launching in Part D in 2027, and CMS extended the Bridge through December 31, 2027. Any page still telling Medicare members to wait for BALANCE in 2027 is out of date.

→ See which Wegovy treatment path matches your coverage and prescribed use

Primary sources: CMS Medicare GLP-1 Bridge overview · Wellcare member page · Wellcare provider bulletin, July 9, 2026

The honest problem: Wellcare cannot process a Bridge request

Here's the frustrating part, stated plainly, because you'll waste weeks if nobody tells you.

Wellcare's own provider bulletin says its Medicare Part D plans are “unable to accept, process, or support any prior authorization requests or reimbursements” connected to the Bridge. It repeats the same boundary later for prior authorizations, claim submissions, and reimbursements.

So if you call Wellcare member services and ask them to approve Wegovy for weight management through the Bridge, the honest answer is that they cannot do it — and it will feel like a door closing. It isn't. They're the wrong system for that request.

And that's actually good news, once you see why.

Because the Bridge runs outside Part D, three things follow that work in your favor:

1. Wellcare's formulary can't block a valid Bridge claim. Whether Wegovy appears on your Wellcare Drug List is not the deciding question for the separate Bridge.
2. Your plan doesn't get a vote on Bridge participation. CMS states that Part D sponsors carry no risk under the Bridge and do not opt in for eligible members to access it.
3. The $50 copay does not rise with a covered Wegovy dose. The same fixed copay applies to an approved Bridge fill, although eligibility, prescription, pharmacy processing, and product availability still have to line up.

If your priority is having one company handle everything under one roof, this will annoy you, and a plan-administered benefit would feel simpler. But because CMS took the Part D plan out of the Bridge's approval and payment flow, the plan's formulary, tier structure, and utilization-management committee do not control an eligible Bridge claim. That trade is worth understanding.

Does your Wellcare plan type qualify for the $50 Bridge?

Bridge eligibility starts with plan type, but an eligible plan type is only the first gate. Standalone Part D plans, Medicare Advantage HMO/HMO-POS/local or regional PPO plans with drug coverage, Special Needs Plans, eligible employer or union group plans, and LI NET can satisfy the plan-type requirement; PFFS and several other plan types cannot unless separate PDP enrollment applies.

This is the table we built by putting CMS's plan-type rules next to Wellcare's Medicare product types. The “yes” entries mean the plan type can qualify. They are not an approval decision.

The finding worth knowing about. Wellcare's Medicare disclaimer identifies HMO, PPO, PFFS, and PDP products. CMS's Bridge rules exclude PFFS enrollees unless they are also enrolled in a standalone PDP, as applicable. Both facts are public. Put them together and a Wellcare PFFS member who reads only a generic “Wellcare members can qualify” statement can get the wrong answer.

If your card says PFFS, check before you get your hopes up. If you are otherwise permitted to enroll in a standalone PDP, that may change the plan-type answer, but changing Medicare coverage can have broader consequences. Ask 1-800-MEDICARE or your local State Health Insurance Assistance Program (SHIP) before changing anything.

If you're a dual (D-SNP), read this before you get excited

Your plan type can qualify. Dual-eligible beneficiaries and Special Needs Plan members are explicitly included when they have an eligible Part D plan and satisfy every other rule.

But here's the part we won't soften: the $50 is still $50 if you receive Extra Help. The Bridge sits outside Part D, so the low-income subsidy doesn't reduce it, it doesn't count toward your Part D deductible, and it doesn't count toward your $2,100 Part D out-of-pocket threshold. Wellcare's bulletin gives the same bottom line — eligible members, including members with LIS, typically pay $50 per fill.

If you're used to paying a few dollars for a prescription, $50 is a real number and we're not going to pretend otherwise.

Now the part that matters: ordinary Wellcare Part D cannot turn weight-management-only Wegovy into a $4 covered prescription. If the Bridge is your only Medicare weight-management treatment path, the practical comparison is the $50 Bridge copay versus another legitimate treatment option — not a low-income Part D copay that the basic benefit is barred from applying to that use.

How to find your plan type in 60 seconds

Look at your member ID card or the cover page of your Evidence of Coverage — the thick booklet Wellcare mailed you. If the plan type is not clear, sign in to Medicare's Plan Finder, call the number on your card, call 1-800-MEDICARE, or ask SHIP.

→ Not sure what coverage you have? Get your personalized treatment path

Primary source: CMS information for pharmacies and beneficiaries

Do you meet the Bridge's medical requirements?

CMS set three clinical pathways, and a prescriber must attest that you meet one of them. The detail that decides many cases: BMI is measured at the time GLP-1 therapy began, not automatically at today's lower weight. Meeting a BMI pathway still does not override plan-type, prescribed-use, diagnosis, or 2026 Part D claim-history exclusions.

You need to be 18 or older, and the requested drug has to be prescribed to reduce excess body weight and maintain weight reduction in combination with current and ongoing lifestyle modification, including structured nutrition and physical activity consistent with the applicable FDA-approved label. Then one of these three:

Pathway 1 — BMI 35 or higher. No additional qualifying condition is required under the Bridge clinical criteria.

Pathway 2 — BMI 30 or higher, plus one of:

• Heart failure with preserved ejection fraction
• High blood pressure that remains uncontrolled — systolic above 140 or diastolic above 90 — while the person is prescribed at least two blood-pressure medications
• Chronic kidney disease, stage 3a or worse

Pathway 3 — BMI 27 or higher, plus one of:

• Prediabetes, as defined by current American Diabetes Association guidelines
• A previous heart attack
• A previous stroke
• Symptomatic peripheral artery disease

The starting-BMI rule that people miss

CMS gives its own example, and it's worth reading twice. Someone who started a GLP-1 in September 2024 at a BMI of 37 and is at 34 when applying in July 2026 can still satisfy the BMI-at-initiation threshold. Therapy can have started before Medicare enrollment and before the Bridge existed.

If you've already lost weight on a GLP-1 and assumed today's BMI automatically ruled you out, it doesn't. Ask your prescriber to pull your starting weight and date from your chart. Other eligibility rules still apply.

The rule that feels backwards

If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced fibrosis, CMS says you are not eligible for the Bridge — even if you meet a BMI pathway and your current Part D plan does not cover a GLP-1 for that condition.

That sounds like a mistake. It isn't. CMS built the Bridge for GLP-1 treatment prescribed solely for weight management when no Part D-coverable GLP-1 indication controls the claim.

This does not mean Wegovy is FDA-approved to treat type 2 diabetes or obstructive sleep apnea. It is not. It means the diagnosed condition belongs in the normal Part D system with a GLP-1 product that is FDA-approved or otherwise coverable for that condition — for example, an appropriate diabetes GLP-1 for type 2 diabetes, Zepbound for its labeled OSA indication, or Wegovy injection for its labeled MASH indication.

Having more diagnoses can lock you out of the cheaper program. If that's you, skip to the Part D section below. Your question is no longer “Can Wellcare cover Wegovy for weight loss?” It is “Which FDA-approved GLP-1 matches the diagnosed condition, and will my exact Wellcare plan cover it?”

The 2026 Part D claim rule almost every summary misses

CMS says a beneficiary who has received a GLP-1 through Part D during calendar year 2026 is not eligible for the Bridge in 2026. CMS checks its own data for Part D-paid claims involving Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, and Trulicity.

That means a person can meet the plan-type and medical criteria and still be rejected because Part D already paid for one of those GLP-1 drugs during 2026. CMS has not yet announced the lookback period it will use for 2027.

This is not a minor footnote. It belongs in the first eligibility conversation with the prescriber because it can change the treatment path before anyone spends time on the Bridge paperwork.

The cardiovascular overlap CMS had to write a rule for

This is the sharpest thing on this page, and it will decide the outcome for a lot of readers.

Pathway 3 includes a previous heart attack, previous stroke, and symptomatic peripheral artery disease. Those can overlap with the established cardiovascular disease behind Wegovy's Part D-coverable cardiovascular indication. So which system handles the prescription?

CMS addressed it directly. The Bridge prior authorization does not require the prescriber to attest that the person is free of established cardiovascular disease. It does require the requested drug to be prescribed for weight reduction and maintenance. When Wegovy is being prescribed to reduce major adverse cardiovascular-event risk, the prescription belongs with the Part D plan — even when weight management is also part of care.

In plain terms: the clinically supported purpose of the prescription decides the treatment path. Not the cheapest price. Not a phrase selected to unlock a payer. The prescriber has to document the medically appropriate indication honestly.

That isn't a loophole and we're not suggesting you coach anyone. It is a real distinction worth discussing out loud because sending a valid cardiovascular request to the Bridge or a weight-management-only request to Wellcare sends the claim to the wrong system.

What the Bridge covers — and one thing it doesn't

The current Bridge list includes:

• All formulations of Wegovy — injection and tablet
• All formulations of Foundayo
• Zepbound KwikPen only — not the single-dose vials or single-dose pens

Ozempic and Mounjaro are not Bridge products.

And one small detail with a real cost attached: pen needles for Zepbound KwikPen are not covered by the Bridge and should not be billed to the Bridge or the Part D plan. CMS says the patient can buy them separately. This needle rule is about Zepbound KwikPen; Wegovy pens are prefilled single-use devices and do not require separately purchased pen needles.

Primary sources: CMS information for providers · CMS information for Part D plans · CMS information for pharmacies

How does a Wellcare member actually get Wegovy through the Bridge?

The process starts with an eligible prescription going to a pharmacy, which submits the claim to Medicare's Bridge processor and triggers the prior-authorization workflow. A Wellcare denial is not required first, and CMS says the recommended obesity diagnosis code and routing note can help but are not mandatory conditions of approval.

This is the section your doctor's office needs. Print it if that's easier.

Step 1 — Confirm the treatment path. Identify the exact plan type, the clinically supported prescribed use, any diagnosis that redirects the request to Part D, and any GLP-1 paid through Part D during 2026. Everything downstream depends on getting this right.

Step 2 — Your prescriber sends a prescription. Not a patient enrollment application. Wellcare's provider bulletin recommends sending the prescription through the standard process with an obesity diagnosis code (E66) and the note “SEND TO BRIDGE FOR WEIGHT MANAGEMENT.” That gives the pharmacy a clear routing instruction.

CMS confirms that the code and annotation are recommended rather than mandatory. They are still worth using because they reduce the chance that a weight-management claim bounces around the Wellcare Part D system first.

Step 3 — The pharmacy submits the claim. The claim goes to Medicare's Bridge BIN and central processor, not to Wellcare. CMS is using Humana's Limited Income Newly Eligible Transition infrastructure as the central processor for prior authorization, claim adjudication, and pharmacy payment.

Step 4 — The prior-authorization request goes to your prescriber. The pharmacy-triggered electronic or fax request typically arrives within 24 to 72 hours.

Here's the unsticking step nobody tells patients: if 72 hours pass and the prescriber has not received the request, Wellcare's bulletin says the prescriber may submit the CMS Bridge prior-authorization form. If the prescription seems stalled, that is the specific thing to ask the office about.

Step 5 — The decision. CMS and Wellcare say approval or denial is communicated to the member by mail and to the prescriber electronically or by fax within 72 hours after the prior authorization is submitted.

Step 6 — Approved fills. Bridge approval is valid through December 31, 2027 under current CMS rules. A new prior authorization is not generally required for later fills of the same approved product; switching from one covered GLP-1 product to another requires a new prior authorization. Each fill is limited to one 28- or 30-day supply. Sixty- and 90-day Bridge fills are not available.

One thing that opens a door

CMS confirms a prescriber does not have to be enrolled in Medicare to write an eligible Bridge prescription or submit the prior authorization. The prescriber cannot be on Medicare's Preclusion List.

Practically, that means if your regular doctor will not engage with the process, another appropriately licensed prescriber may be able to evaluate you and handle it — including a clinician who practices through telehealth. That is a genuine option. It is not a guarantee that a particular service accepts your coverage, will prescribe Wegovy, or will complete Bridge paperwork.

What not to do

• Don't ask Wellcare to process the Bridge request. It can't.
• Don't treat a pharmacy “not covered” message as the final answer. It may be a routing response, not a final coverage decision.
• Don't submit the same prescription under conflicting medical reasons hoping one sticks.
• Don't use a commercial savings card or discount coupon on a Bridge claim. CMS bars coupons and discount programs from Bridge claims.
• Don't expect a 60- or 90-day Bridge fill. CMS permits one monthly supply per fill.

Say this to your doctor

“I'd like to know whether you're prescribing Wegovy for weight management, to reduce my cardiovascular risk, or for MASH, because that decides whether the request goes to Medicare's GLP-1 Bridge or my Wellcare Part D plan. If it is the Bridge, please consider including E66 and the note ‘SEND TO BRIDGE FOR WEIGHT MANAGEMENT,’ use my BMI from when GLP-1 therapy began, and check whether Part D paid for any GLP-1 for me during 2026.”

Say this to your pharmacy

“Which payer or processor did you submit this claim to, and what exact response came back? If this is a weight-management prescription and my prescriber believes I may qualify, can you submit it to the Medicare GLP-1 Bridge processor instead of Wellcare?”

If you or your prescriber get stuck

• Members: Call 1-800-MEDICARE (1-800-633-4227) or contact your local SHIP. CMS directs beneficiaries there for Bridge information.
• Prescribers: The Bridge provider line is 855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern.
• Pharmacies: Use CMS's current pharmacy instructions and payer sheet for the Bridge BIN/PCN and help-desk process.

→ Build my personalized doctor-and-pharmacy action plan

Primary sources: Wellcare provider bulletin · CMS provider instructions · CMS pharmacy instructions

When does Wellcare cover Wegovy through Part D?

Wellcare Part D may cover Wegovy when it is prescribed for a Part D-coverable FDA-approved use: reducing major cardiovascular-event risk in the labeled adult population, or treating noncirrhotic MASH with moderate-to-advanced fibrosis using Wegovy injection. Coverage still depends on the exact plan's Drug List, utilization rules, and exception process.

If your prescriber is writing Wegovy to reduce the risk of cardiovascular death, nonfatal heart attack, or nonfatal stroke, and you have established cardiovascular disease plus overweight or obesity, this is the Part D treatment path.

The same is true for Wegovy injection prescribed for noncirrhotic MASH with F2–F3 fibrosis in an adult.

Two things have to be right:

The request must identify the medically supported Part D-coverable indication. A weight-management-only Wegovy request sent to ordinary Part D hits the statutory exclusion. The correction is to use the correct coverage system, not to argue that Wellcare should cover an excluded use.

The documentation has to support the request. Your prescriber needs the diagnosis, relevant clinical history, and the information required by the plan's current prior-authorization or formulary-exception process.

What if Wegovy is not on your Wellcare Drug List?

A Part D-coverable indication does not guarantee that Wegovy appears on the formulary. CMS says plans must continue to use their normal formulary-exception processes for Part D-coverable GLP-1 uses even when the drug is not listed.

That means “not on formulary” can still leave a legitimate next step:

1. Ask for a coverage determination.
2. Ask whether the request is a formulary exception, prior authorization, or both.
3. Have the prescriber send the supporting statement the plan requires.
4. Address the plan's covered alternatives and explain why they would not be as effective or could cause adverse effects when that is medically accurate.
5. Use the denial notice's appeal instructions if Wellcare denies the Part D request.

Why the cheaper-looking treatment path may not be yours to choose

Most pages treat the Bridge-versus-Part-D cost comparison as obvious. It isn't.

The Bridge is a fixed $50 per covered fill, but none of that spending counts toward the Part D deductible or the $2,100 out-of-pocket threshold, and Extra Help does not reduce it.

A covered Part D claim can cost more early in the year, but eligible out-of-pocket spending counts toward the 2026 threshold. After a member reaches $2,100 in out-of-pocket spending on covered Part D drugs, the member pays nothing out of pocket for covered Part D drugs for the rest of the calendar year.

The treatment path is not a menu where you pick the lower annual total. The prescriber has to submit the clinically accurate use. This table exists so you understand the financial consequences of the correct pathway — not so anyone changes an indication to chase a price.

Primary sources: CMS information for Part D plans · Medicare 2026 Part D costs

Is Wegovy on the Wellcare drug list in 2026?

There is no single national Wellcare Drug List that answers every member's question. Wellcare offers standalone PDP formularies and Medicare Advantage formularies that vary by plan and state and are updated during the year. In our August 4 sample, Wegovy was absent from three current official files, but that finding does not prove a universal Wellcare exclusion.

We went looking. Here's exactly what we did and what we found.

What we checked

On August 4, 2026, we reviewed three official Wellcare formulary files marked updated August 1, 2026. We searched each PDF for WEGOVY, checked the W section and alphabetical index, and searched OZEMPIC and MOUNJARO as control terms to confirm that the files and relevant drug sections were searchable.

What this shows, and only this: Wegovy was absent from all three files we sampled. That does not prove every Wellcare plan excludes it. This is a purposive three-file spot-check, not a statistically representative survey.

What it does demonstrate is why a “not on the list” result and Bridge eligibility are two completely different questions — and why searching your Drug List and giving up can be an expensive mistake.

It also does not tell you whether a formulary exception would be approved, what your state Medicaid program covers, or that Ozempic or Mounjaro can be substituted for Wegovy. Those are separate clinical and coverage questions.

Official sampled files: HPMS 26195 · HPMS 26187 · HPMS 26330

How to read your own Drug List

1. Find your exact plan name and contract/plan number on your member card.
2. Open the current 2026 Drug List for that exact plan.
3. Check the file's “updated” date.
4. Search both “Wegovy” and “semaglutide.”
5. Check the alphabetical index by hand — PDF text search can miss broken line wraps.
6. Check the separate prior-authorization, step-therapy, and quantity-limit documents.
7. Save the PDF and take a dated screenshot showing the plan name, plan year, drug result, and restrictions.
8. Call the number on your card and confirm that the file applies to your exact plan.

In the sampled files, GLP-1 medications appear within endocrine/diabetes sections rather than a simple consumer-facing “weight loss” category. People hunt for a weight-loss heading, don't find one, and conclude the file is broken.

What the common formulary symbols mean

Wellcare Value Script 2026 cost sharing in the sampled formulary

The HPMS 26195 formulary displays this standard cost-sharing table. A member's Evidence of Coverage, LIS status, benefit phase, and pharmacy choice control the actual amount.

Three rules from the same formulary that change outcomes:

Tier 5 drugs cannot be moved to a lower tier through a tiering exception. A formulary or utilization-management exception may still be a separate question when the plan rules allow it.

The decision clock depends on the prescriber's supporting statement. Wellcare's coverage-determination materials state that the plan generally decides within 72 hours after receiving the supporting statement, or 24 hours for an expedited request that qualifies.

Temporary transition fills are not a permanent approval. The sampled formulary says a new or continuing member may receive a temporary 30-day supply during the first 90 days in specified circumstances when a drug is non-formulary or newly restricted. That supply is time to resolve coverage — not proof that future fills will be paid.

How much does Wegovy cost with Wellcare in 2026?

There is no single Wellcare price for Wegovy. Bridge members pay $50 per covered monthly fill, and the payment does not count toward the Part D deductible or $2,100 out-of-pocket threshold. A Wellcare Part D-covered Wegovy claim has plan-specific cost sharing and does count under normal Part D rules. Self-pay pricing sits outside both systems.

For 2026, no Medicare drug plan may have a deductible above $615, and the Part D out-of-pocket threshold is $2,100. After reaching that threshold through qualifying covered-drug spending, the member has no out-of-pocket cost for covered Part D drugs for the rest of the calendar year.

We won't publish a universal “Wegovy costs $X with Wellcare” number, and you should distrust any page that does. The exact plan, formulary, deductible, benefit phase, pharmacy, approved use, exception status, and subsidy all move that number.

Current published Wegovy self-pay prices

These are Novo Nordisk's published prices checked August 4, 2026. Eligibility and restrictions apply, and Novo Nordisk says it may modify or cancel the offers.

Published list price without the self-pay program: $1,349.02 for a monthly supply.

That August 31 date is real and published, not a countdown timer we invented. It belongs here because it materially changes the 4 mg tablet price. Recheck it before relying on the number.

The commercial savings card is not the Bridge

Novo Nordisk's commercial-insurance savings terms exclude government beneficiaries from the “as little as $25” commercial offer. That is the manufacturer's published eligibility rule.

CMS separately says coupons and discount programs cannot be applied to Bridge claims. If a page tells you to stack a Wegovy commercial savings card with a $50 Bridge claim, it is wrong.

A government-insured person may still encounter a separate self-pay offer that requires the purchase to stay outside the insurance claim and forbids reimbursement or credit toward the plan deductible or out-of-pocket limit. Read the current terms for the exact channel before paying.

Primary sources: Medicare 2026 Part D costs · Novo Nordisk Wegovy price guide · Wegovy cost and coverage terms

Why did Wellcare deny Wegovy, and what should you do now?

The right response depends entirely on which “no” you received. A weight-management exclusion points toward a Bridge eligibility check. A wrong-processor response means the pharmacy may need to reroute the claim. A non-formulary denial for a Part D-coverable use calls for Wellcare's coverage-determination or formulary-exception process.

Bridge denials work differently and you need to know this. CMS states that the Bridge has no formal appeal process. The prescriber can resubmit corrected, updated, or additional information. That can be faster than a traditional appeal — but the prescriber has to make the resubmission.

Part D denials do have appeal rights. For a Wellcare coverage determination, the plan generally decides within 72 hours after receiving the prescriber's supporting statement, or within 24 hours for a qualifying expedited request. A denial notice must explain the next appeal step.

Do you need a Wellcare denial before trying the Bridge?

No. CMS says a Part D denial is not required before the pharmacy sends a potentially eligible weight-management claim to the Bridge processor.

Say this to Wellcare

“I'm calling about Wegovy prescribed for [my documented indication]. Please confirm whether it is on my exact plan's current Drug List, which restrictions apply, and whether the next step is a prior authorization, coverage determination, or formulary exception. If this is a weight-management-only prescription, I understand Wellcare is not the Bridge processor and I am not asking you to process a Bridge request.”

That last sentence saves the call. It tells the representative you already understand the boundary and moves the conversation to the part Wellcare can actually answer.

→ Turn my rejection into the right next step

Does Wellcare Medicaid cover Wegovy?

WellCare-branded Medicaid coverage exists in some states, and Medicaid rules are not the same as Medicare Part D or the Medicare GLP-1 Bridge. A Medicaid-only member must use the exact state's preferred drug list, covered-indication rules, and prior-authorization process; a dual-eligible member may separately have a Bridge treatment path through eligible Part D coverage.

Do not assume the word “WellCare” on a card automatically means Medicare. Confirm whether the coverage is:

• Medicare Advantage with Part D
• A standalone Part D plan
• A D-SNP with Medicare and Medicaid
• Medicaid-only managed care
• Another Centene plan with a different brand name

We're not going to publish a national count of “states that cover it.” Those numbers go stale quickly, and they hide the distinctions that actually matter — fee-for-service versus managed care, effective dates, covered uses, continuation rules, preferred products, and the documentation each state requires.

For Medicaid-only coverage:

1. Identify the state Medicaid program and managed-care plan.
2. Open the current preferred drug list and prior-authorization criteria.
3. Search the exact Wegovy formulation and dose.
4. Confirm whether the listed use is weight management, cardiovascular risk, MASH, or another stated category.
5. Save the effective date and the exact coverage language.
6. Call the member number on the card before relying on an undated summary.

If you have both Medicare and Medicaid, go back to the plan-type table. An eligible D-SNP can satisfy the Bridge plan-type gate, but dual status does not waive the prescribed-use, clinical, diagnosis, or 2026 Part D claim-history rules.

“After weeks of searching I found nothing”

We looked for real people describing this problem in their own words because we wanted to check that we were solving the right one.

In the AARP Medicare & Insurance forum, a member posting as LBL was hunting for a Part D plan that would cover Wegovy for prediabetes. Their post listed four things they needed: which plan covered it, for which diagnoses, at what level, and whether preapproval was required. Then this line:

“After weeks of intermittent searching I have found NO useful information from any source.”

Other participants in the same discussion described being bounced among clinicians, prescriptions, plan searches, and cash prices without a workable answer.

Those posts predate the Bridge. Read them against today's rules and something jumps out: BMI 27 or higher plus prediabetes is now one of CMS's three clinical pathways. That does not guarantee the $50 treatment path. The member also needs an eligible Part D plan, a weight-management prescription, no diagnosis or claim-history exclusion, ongoing labeled lifestyle modification, and central-processor approval.

We can't tell you what happened to anyone in that thread, and we won't pretend to. But that's the gap this page exists to close. If you've been where LBL was, the rules changed on July 1, 2026 — and the answer is now specific enough to act on.

Voice-of-customer source: AARP Medicare & Insurance community discussion

What if none of the Medicare treatment paths work for you?

If you do not qualify for the Bridge and do not have a workable Part D-covered Wegovy pathway, FDA-approved self-pay care is one fallback. Check the insurance and exception paths first: cash pay sits outside Wellcare, does not count toward Part D spending, and adds any telehealth membership or visit fee to the medication price.

Before you go here, exhaust the correct covered pathways. An apparent dead end is often a routing problem, a missing prior authorization, or an untried formulary exception. Cash pay is usually more expensive than the $50 Bridge and we'd rather you not need it.

The manufacturer self-pay table above shows the medication prices. A telehealth program can add clinical evaluation, prescribing, follow-up, and fulfillment coordination — but it does not transform a cash purchase into Wellcare coverage.

If you're paying cash anyway

Ro carries FDA-approved Wegovy in pen and tablet form. Be clear about what you're buying: the Ro Body membership is $39 for the first month, then as low as $74 per month with an annual plan paid upfront, or $149 per month if you remain monthly. Medication is billed separately.

And here's the limitation we're not going to bury: Ro's published government-insurance policy says Medicare, Medicare supplement, and TRICARE members may still be eligible for certain cash-pay treatment options. It does not present Ro as a way to bill Wellcare, process a Bridge claim, or obtain a government-plan reimbursement. Ro also says its insurance concierge is available for FEHB coverage; do not assume that service applies to an ordinary Wellcare Medicare plan.

If having someone process the Medicare Bridge is what you need, Ro is not the Bridge processor. Go back to the Bridge section, use 1-800-MEDICARE or SHIP as a member, and have the prescriber and pharmacy use CMS's current process.

But if you've already established that you're paying cash regardless, Ro gives you an online clinical evaluation, a licensed prescriber review, FDA-approved medication when prescribed, and published membership pricing before you commit.

→ See Ro's current Wegovy eligibility and cash pricing (sponsored affiliate link; opens in a new tab)

Eligibility is determined after clinical review. Membership and medication are billed separately. This is a cash-pay comparison, not a way to bill Wellcare or the Medicare GLP-1 Bridge.

If you'd rather choose an individual clinician or a different ongoing-care model, Sesame lists online weight-management appointments and FDA-approved medication pathways. Check the current visit, program, and medication prices at the time you use it; no Sesame promotion is quoted here because the visible promotional terms available during this audit were not current enough to publish confidently.

One thing we won't recommend here

Compounded semaglutide is not FDA-approved Wegovy. It is a different regulatory category, it is not included as Wegovy in the Medicare GLP-1 Bridge, and it is not a way to use Wellcare's Wegovy benefit.

A Medicare denial does not make a compounded product medically appropriate for you. That decision belongs with a licensed clinician after an honest discussion of the product, pharmacy, legal status, risks, alternatives, and why an FDA-approved treatment path is not being used. There are no compounded-provider links on this page, and that's deliberate.

Provider primary sources: Ro pricing · Ro government-insurance policy · Sesame online weight-loss program

What did The RX Index actually verify?

We built this page from dated primary documents rather than a carrier-wide assumption. The work included CMS's current Bridge instructions, Wellcare's member and provider pages, the current FDA label, Medicare's 2026 cost rules, three official Wellcare formularies, Novo Nordisk's published self-pay terms, and Ro's current pricing and government-insurance policy.

What we did not do: we did not enroll a person, submit a real prior authorization, access a member account, test the pharmacy claim flow, or verify every Wellcare plan in the country. We did not make a clinical eligibility determination. Your prescriber, pharmacy, Wellcare, and Medicare's central processor make the decisions that apply to you.

Who made this and why: The RX Index Editorial Team. We build these pages by pulling the primary documents ourselves — CMS rules, insurer bulletins, formulary PDFs, FDA labels, and current price terms — and placing them side by side. We built this one because two Wellcare pages currently give members and providers different levels of information about the same program, and members are the ones most likely to lose time when the systems are confused.

Does Wellcare cover Wegovy? Frequently asked questions

These are the plan-type, indication, cost, and process questions most likely to send a Wellcare member back to search. The conditions stay in every answer because reducing this subject to a universal yes or no would be misleading.

Does Wellcare cover Wegovy for weight loss?

Not through ordinary Part D when Wegovy is prescribed only for weight management. An eligible member with qualifying Part D coverage may instead get Wegovy through the separate Medicare GLP-1 Bridge for a $50 copay per covered monthly fill if every plan-type, clinical, diagnosis, use, and claim-history rule is met.

Can I get Wegovy for $50 if I have Wellcare?

Possibly. Having Wellcare is not enough. You need an eligible Medicare Part D plan type, a weight-management prescription, one of CMS's clinical pathways, no disqualifying diagnosis for Bridge purposes, no Part D-paid GLP-1 claim during the applicable 2026 lookback, and central-processor approval. The $50 is a Medicare Bridge copay, not a Wellcare copay.

Does Wellcare cover Wegovy for heart disease?

Wellcare Part D may cover Wegovy for its FDA-approved cardiovascular-risk indication in adults with established cardiovascular disease and either overweight or obesity. Coverage still depends on the exact Drug List, prior-authorization or exception criteria, and supporting documentation.

Does Wellcare cover Wegovy for MASH?

Possibly. Wegovy injection is FDA-approved under accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with F2–F3. That request goes through Wellcare Part D rather than the Bridge, and coverage is plan-specific. Wegovy tablets are not labeled for MASH.

I have type 2 diabetes. Can I use the Bridge for Wegovy?

CMS says a type 2 diabetes diagnosis makes the person ineligible for the Bridge, even if the other clinical criteria are met. That does not make Wegovy a type 2 diabetes drug; Wegovy is not FDA-approved to treat diabetes. Ask the prescriber which diabetes-labeled GLP-1 and Part D treatment path, if any, fit the diagnosis.

I have moderate-to-severe sleep apnea. Can I use the Bridge for Wegovy?

CMS says that diagnosis makes the person ineligible for the Bridge. Wegovy is not FDA-approved to treat obstructive sleep apnea. Zepbound has an FDA-approved OSA indication for specified adults with obesity, so a medically appropriate OSA GLP-1 request belongs in ordinary Part D rather than the weight-management Bridge.

What if Part D paid for Ozempic, Mounjaro, or another GLP-1 for me in 2026?

CMS says a person who received a GLP-1 through Part D during calendar year 2026 is not eligible for the Bridge in 2026. CMS reviews claims for Zepbound, Mounjaro, Foundayo, Rybelsus, Ozempic, Wegovy, Saxenda, Victoza, and Trulicity. CMS has not yet set the 2027 lookback period.

Is Wegovy on the Wellcare Value Script Drug List?

We did not find a Wegovy entry in the official HPMS 26195 file marked updated August 1, 2026. That is one current formulary, not a universal Wellcare answer. Check your exact plan's current file and remember that Bridge eligibility is separate from the Wellcare formulary.

Does my doctor send the Bridge request to Wellcare?

No. Wellcare's provider bulletin says its Part D plans cannot accept, process, or support Bridge prior authorizations, claims, or reimbursements. The prescription, pharmacy claim, and prior authorization follow Medicare's central-processor process.

Do I need a Wellcare denial before using the Bridge?

No. CMS says a Part D denial is not required. If the prescriber believes you may qualify, the pharmacy can submit the claim directly to the Bridge processor.

How long does the Bridge prior authorization take?

The pharmacy-triggered request typically reaches the prescriber within 24 to 72 hours. CMS and Wellcare say the decision is communicated within 72 hours after the prior authorization is submitted. Missing documentation, wrong routing, or an unreceived request can add time.

What happens if the prescriber never receives the request?

If 72 hours pass, Wellcare's provider bulletin says the prescriber may use the CMS Bridge prior-authorization form. The office should first confirm that the pharmacy submitted the claim to the Bridge process rather than Wellcare Part D.

Can I appeal a Bridge denial?

There is no formal Bridge appeal process. The prescriber may resubmit corrected, updated, or additional information. A Wellcare Part D denial is different and carries the normal Part D appeal rights described in the denial notice.

Does Extra Help reduce the $50?

No. The Bridge operates outside Part D, so the low-income subsidy does not reduce the $50 copay. The payment also does not count toward the Part D deductible or the $2,100 out-of-pocket threshold.

Can a Wellcare D-SNP member qualify?

The plan type can qualify. CMS expressly includes eligible Special Needs Plans and dual-eligible beneficiaries enrolled in eligible Part D plan types. The member still has to satisfy every clinical, prescribed-use, diagnosis, and claim-history rule.

What if my BMI has already dropped below the cutoff?

The prescriber uses BMI at the time GLP-1 therapy began for the Bridge threshold. Therapy may have started before Medicare enrollment or before July 1, 2026. A lower BMI today does not automatically disqualify you, but every other rule still applies.

Are pen needles covered?

The separate-needle exclusion applies to Zepbound KwikPen. CMS says those pen needles are not covered by the Bridge or the Part D plan and can be purchased separately. Wegovy's prefilled single-use pens do not use separately purchased pen needles.

Can I get a 90-day Bridge fill?

No. CMS limits the Bridge to one 28- or 30-day supply per fill. Sixty- and 90-day fills are not available.

Do I need a new prior authorization every month?

Not for routine later fills of the same approved Bridge product. Current CMS guidance says approval remains valid through December 31, 2027 and a new prior authorization is generally required if the person switches from one covered GLP-1 product to another.

Does Wellcare Medicaid cover Wegovy?

It depends on the state program, managed-care plan, current preferred drug list, covered use, and prior-authorization criteria. Do not apply Medicare Bridge rules to Medicaid-only coverage. A dual-eligible member may separately have an eligible Part D treatment path.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved brand-name medication. Compounded semaglutide is a different regulatory category, is not FDA-approved as Wegovy, and is not included as Wegovy in the Medicare GLP-1 Bridge or a Wellcare Wegovy benefit.

What happens after December 31, 2027?

The Bridge is currently scheduled to run through December 31, 2027. CMS has confirmed that the Medicare Part D portion of BALANCE is not launching in 2027. What follows depends on future CMS action, so do not build a long-term treatment budget on an assumption that the $50 program will continue after its announced end date.

Still not sure which GLP-1 program is right for you? Take our free two-minute matching quiz.

→ Find My GLP-1 Path

This page covers FDA-approved Wegovy and the coverage systems that may apply to it. Compounded semaglutide is a separate category and is not a Wellcare or Medicare GLP-1 Bridge substitute.

Related guides

• Does Medicare cover Wegovy for weight loss?
• Medicare GLP-1 Bridge: how the application process works
• The Medicare GLP-1 Bridge and the Part D coverage gap
• What happens after the Medicare GLP-1 Bridge ends?
• How to get insurance to cover a GLP-1

Primary sources

• CMS: Medicare GLP-1 Bridge overview
• CMS: Information for providers
• CMS: Information for pharmacies
• CMS: Information for Part D plans
• Medicare.gov: Weight-loss drugs and the GLP-1 Bridge
• Wellcare: GLP-1 Medicare Part D Bridge provider bulletin, July 9, 2026
• Wellcare: Does Medicare cover weight-loss drugs?
• FDA: Current Wegovy prescribing information
• FDA: Cardiovascular-risk approval
• FDA: MASH approval
• Medicare.gov: 2026 Part D costs
• NovoCare: Wegovy price guide
• Ro: Weight-loss program pricing
• Ro: Government-insurance policy

This page is for general information and is not medical advice, a coverage determination, or a guarantee of approval. Wegovy carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; it is unknown whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people with a prior serious hypersensitivity reaction to semaglutide or its excipients. Review the current FDA prescribing information with your prescriber. The RX Index is not affiliated with Wellcare, Centene, CMS, Medicare, Novo Nordisk, Ro, or Sesame.